{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:45:56Z","timestamp":1786981556320,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s11060-022-03970-4","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:03:49Z","timestamp":1646265829000},"page":"355-364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients"],"prefix":"10.1007","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3935-0924","authenticated-orcid":false,"given":"Charles","family":"de Marcellus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnault","family":"Tauzi\u00e8de-Espariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Cuinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pasqualini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu P.","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Beccaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Puget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Boddaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Figarella-Branger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"De Carli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Bourdeaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Fouyssac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne I.","family":"Bertozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Butel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Valteau-Couanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Varlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Grill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"issue":"Suppl 4","key":"3970_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","volume":"17","author":"QT Ostrom","year":"2015","unstructured":"Ostrom QT, Gittleman H, Fulop J et al (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008\u20132012. Neuro-oncology 17(Suppl 4):iv1\u2013iv62. https:\/\/doi.org\/10.1093\/neuonc\/nov189","journal-title":"Neuro-oncology"},{"key":"3970_CR2","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1200\/JCO.1997.15.8.2792","volume":"15","author":"A Gajjar","year":"1997","unstructured":"Gajjar A, Sanford RA, Heideman R et al (1997) Low-grade astrocytoma: a decade of experience at St. Jude Children\u2019s Research Hospital. J Clin Oncol 15:2792\u20132799","journal-title":"J Clin Oncol"},{"key":"3970_CR3","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1200\/JCO.2003.01.017","volume":"21","author":"DC Bowers","year":"2003","unstructured":"Bowers DC, Gargan L, Kapur P et al (2003) Study of the MIB-1 labeling index as a predictor of tumor progression in pilocytic astrocytomas in children and adolescents. J Clin Oncol 21:2968\u20132973. https:\/\/doi.org\/10.1200\/JCO.2003.01.017","journal-title":"J Clin Oncol"},{"key":"3970_CR4","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1200\/JCO.2008.20.9494","volume":"27","author":"TE Merchant","year":"2009","unstructured":"Merchant TE, Kun LE, Wu S et al (2009) Phase II trial of conformal radiation therapy for pediatric low-grade glioma. J Clin Oncol 27:3598\u20133604. https:\/\/doi.org\/10.1200\/JCO.2008.20.9494","journal-title":"J Clin Oncol"},{"key":"3970_CR5","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1200\/JCO.2002.08.087","volume":"20","author":"M Massimino","year":"2002","unstructured":"Massimino M, Spreafico F, Cefalo G et al (2002) High response rate to cisplatin\/etoposide regimen in childhood low-grade glioma. J Clin Oncol 20:4209\u20134216","journal-title":"J Clin Oncol"},{"key":"3970_CR6","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1200\/JCO.2002.12.008","volume":"20","author":"S Gururangan","year":"2002","unstructured":"Gururangan S, Cavazos CM, Ashley D et al (2002) Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol 20:2951\u20132958","journal-title":"J Clin Oncol"},{"key":"3970_CR7","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1200\/JCO.2011.34.5843","volume":"30","author":"E Bouffet","year":"2012","unstructured":"Bouffet E, Jakacki R, Goldman S et al (2012) Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 30:1358\u20131363. https:\/\/doi.org\/10.1200\/JCO.2011.34.5843","journal-title":"J Clin Oncol"},{"key":"3970_CR8","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.1200\/JCO.2003.03.043","volume":"21","author":"V Laithier","year":"2003","unstructured":"Laithier V, Grill J, Le Deley M-C et al (2003) Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy\u2013results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol 21:4572\u20134578. https:\/\/doi.org\/10.1200\/JCO.2003.03.043","journal-title":"J Clin Oncol"},{"key":"3970_CR9","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1200\/JCO.2011.36.6054","volume":"30","author":"JL Ater","year":"2012","unstructured":"Ater JL, Zhou T, Holmes E et al (2012) Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children\u2019s Oncology Group. J Clin Oncol 30:2641\u20132647. https:\/\/doi.org\/10.1200\/JCO.2011.36.6054","journal-title":"J Clin Oncol"},{"key":"3970_CR10","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ejca.2017.04.019","volume":"81","author":"AK Gnekow","year":"2017","unstructured":"Gnekow AK, Walker DA, Kandels D et al (2017) A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (\u2264 16 years) low grade glioma\u2014a final report. Eur J Cancer 81:206\u2013225. https:\/\/doi.org\/10.1016\/j.ejca.2017.04.019","journal-title":"Eur J Cancer"},{"key":"3970_CR11","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/pbc.21911","volume":"52","author":"V de Haas","year":"2009","unstructured":"de Haas V, Grill J, Raquin M-A et al (2009) Relapses of optic pathway tumors after first-line chemotherapy. Pediatr Blood Cancer 52:575\u2013580. https:\/\/doi.org\/10.1002\/pbc.21911","journal-title":"Pediatr Blood Cancer"},{"key":"3970_CR12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3171\/ped.2006.104.5.314","volume":"104","author":"U Bartels","year":"2006","unstructured":"Bartels U, Hawkins C, Jing M et al (2006) Vascularity and angiogenesis as predictors of growth in optic pathway\/hypothalamic gliomas. J Neurosurg 104:314\u2013320. https:\/\/doi.org\/10.3171\/ped.2006.104.5.314","journal-title":"J Neurosurg"},{"key":"3970_CR13","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber H-P, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669\u2013676. https:\/\/doi.org\/10.1038\/nm0603-669","journal-title":"Nat Med"},{"key":"3970_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nrc2346","volume":"8","author":"RK Jain","year":"2008","unstructured":"Jain RK (2008) Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 8:309\u2013316. https:\/\/doi.org\/10.1038\/nrc2346","journal-title":"Nat Rev Cancer"},{"key":"3970_CR15","doi-asserted-by":"publisher","first-page":"29889","DOI":"10.18632\/oncotarget.5092","volume":"6","author":"F Gremonprez","year":"2015","unstructured":"Gremonprez F, Descamps B, Izmer A et al (2015) Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model. Oncotarget 6:29889\u201329900. https:\/\/doi.org\/10.18632\/oncotarget.5092","journal-title":"Oncotarget"},{"key":"3970_CR16","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1200\/JCO.1999.17.5.1516","volume":"17","author":"HS Friedman","year":"1999","unstructured":"Friedman HS, Petros WP, Friedman AH et al (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17:1516\u20131525","journal-title":"J Clin Oncol"},{"key":"3970_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1215\/15228517-2008-075","volume":"11","author":"JJ Vredenburgh","year":"2009","unstructured":"Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS (2009) Experience with irinotecan for the treatment of malignant glioma. Neurooncology 11:80\u201391. https:\/\/doi.org\/10.1215\/15228517-2008-075","journal-title":"Neurooncology"},{"key":"3970_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10456-011-9209-1","volume":"14","author":"P Sapra","year":"2011","unstructured":"Sapra P, Kraft P, Pastorino F et al (2011) Potent and sustained inhibition of HIF-1\u03b1 and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects. Angiogenesis 14:245\u2013253. https:\/\/doi.org\/10.1007\/s10456-011-9209-1","journal-title":"Angiogenesis"},{"key":"3970_CR19","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342. https:\/\/doi.org\/10.1056\/NEJMoa032691","journal-title":"N Engl J Med"},{"key":"3970_CR20","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542\u20132550. https:\/\/doi.org\/10.1056\/NEJMoa061884","journal-title":"N Engl J Med"},{"key":"3970_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427\u2013434. https:\/\/doi.org\/10.1056\/NEJMoa021491","journal-title":"N Engl J Med"},{"key":"3970_CR22","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484\u20132496. https:\/\/doi.org\/10.1056\/NEJMoa1103799","journal-title":"N Engl J Med"},{"key":"3970_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ejca.2017.06.015","volume":"83","author":"JC Chisholm","year":"2017","unstructured":"Chisholm JC, Merks JHM, Casanova M et al (2017) Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). Eur J Cancer 83:177\u2013184. https:\/\/doi.org\/10.1016\/j.ejca.2017.06.015","journal-title":"Eur J Cancer"},{"key":"3970_CR24","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1200\/JCO.2017.76.0611","volume":"36","author":"J Grill","year":"2018","unstructured":"Grill J, Massimino M, Bouffet E et al (2018) Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma. J Clin Oncol 36:951\u2013958. https:\/\/doi.org\/10.1200\/JCO.2017.76.0611","journal-title":"J Clin Oncol"},{"key":"3970_CR25","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/pbc.21935","volume":"52","author":"RJ Packer","year":"2009","unstructured":"Packer RJ, Jakacki R, Horn M et al (2009) Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 52:791\u2013795. https:\/\/doi.org\/10.1002\/pbc.21935","journal-title":"Pediatr Blood Cancer"},{"key":"3970_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/pbc.24066","volume":"59","author":"M-L Couec","year":"2012","unstructured":"Couec M-L, Andr\u00e9 N, Thebaud E et al (2012) Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends. Pediatr Blood Cancer 59:34\u201338. https:\/\/doi.org\/10.1002\/pbc.24066","journal-title":"Pediatr Blood Cancer"},{"key":"3970_CR27","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/pbc.24297","volume":"60","author":"EI Hwang","year":"2013","unstructured":"Hwang EI, Jakacki RI, Fisher MJ et al (2013) Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer 60:776\u2013782. https:\/\/doi.org\/10.1002\/pbc.24297","journal-title":"Pediatr Blood Cancer"},{"key":"3970_CR28","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1365-2990.2011.01160.x","volume":"37","author":"AH Sikkema","year":"2011","unstructured":"Sikkema AH, de Bont ESJM, Molema G et al (2011) Vascular endothelial growth factor receptor 2 (VEGFR-2) signalling activity in paediatric pilocytic astrocytoma is restricted to tumour endothelial cells. Neuropathol Appl Neurobiol 37:538\u2013548. https:\/\/doi.org\/10.1111\/j.1365-2990.2011.01160.x","journal-title":"Neuropathol Appl Neurobiol"},{"key":"3970_CR29","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/neuonc\/not154","volume":"16","author":"S Gururangan","year":"2014","unstructured":"Gururangan S, Fangusaro J, Poussaint TY et al (2014) Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas\u2013a Pediatric Brain Tumor Consortium study. Neurooncology 16:310\u2013317. https:\/\/doi.org\/10.1093\/neuonc\/not154","journal-title":"Neurooncology"},{"key":"3970_CR30","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2009.26.8789","volume":"28","author":"S Gururangan","year":"2010","unstructured":"Gururangan S, Chi SN, Young Poussaint T et al (2010) Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol 28:3069\u20133075. https:\/\/doi.org\/10.1200\/JCO.2009.26.8789","journal-title":"J Clin Oncol"},{"key":"3970_CR31","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1016\/S1470-2045(20)30064-4","volume":"21","author":"J Fangusaro","year":"2020","unstructured":"Fangusaro J, Witt O, Hern\u00e1iz Driever P et al (2020) Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol 21:e305\u2013e316. https:\/\/doi.org\/10.1016\/S1470-2045(20)30064-4","journal-title":"Lancet Oncol"},{"key":"3970_CR32","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1093\/neuonc\/noq092","volume":"12","author":"T Stokland","year":"2010","unstructured":"Stokland T, Liu J-F, Ironside JW et al (2010) A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neurooncology 12:1257\u20131268. https:\/\/doi.org\/10.1093\/neuonc\/noq092","journal-title":"Neurooncology"},{"key":"3970_CR33","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1200\/JCO.2016.68.1585","volume":"34","author":"A Lassaletta","year":"2016","unstructured":"Lassaletta A, Scheinemann K, Zelcer SM et al (2016) Phase II weekly vinblastine for chemotherapy-na\u00efve children with progressive low-grade glioma: a Canadian Pediatric Brain Tumor Consortium Study. J Clin Oncol 34:3537\u20133543. https:\/\/doi.org\/10.1200\/JCO.2016.68.1585","journal-title":"J Clin Oncol"},{"key":"3970_CR34","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1002\/cncr.29987","volume":"122","author":"JL Ater","year":"2016","unstructured":"Ater JL, Xia C, Mazewski CM et al (2016) Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: a report from the Children\u2019s Oncology Group. Cancer 122:1928\u20131936. https:\/\/doi.org\/10.1002\/cncr.29987","journal-title":"Cancer"},{"key":"3970_CR35","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s00247-008-1003-x","volume":"38","author":"SC Jost","year":"2008","unstructured":"Jost SC, Ackerman JW, Garbow JR et al (2008) Diffusion-weighted and dynamic contrast-enhanced imaging as markers of clinical behavior in children with optic pathway glioma. Pediatr Radiol 38:1293\u20131299. https:\/\/doi.org\/10.1007\/s00247-008-1003-x","journal-title":"Pediatr Radiol"},{"key":"3970_CR36","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1007\/s00247-018-4154-4","volume":"48","author":"E Maloney","year":"2018","unstructured":"Maloney E, Stanescu AL, Perez FA et al (2018) Surveillance magnetic resonance imaging for isolated optic pathway gliomas: is gadolinium necessary? Pediatr Radiol 48:1472\u20131484. https:\/\/doi.org\/10.1007\/s00247-018-4154-4","journal-title":"Pediatr Radiol"},{"key":"3970_CR37","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1345\/aph.1L426","volume":"43","author":"SM Gressett","year":"2009","unstructured":"Gressett SM, Shah SR (2009) Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 43:490\u2013501. https:\/\/doi.org\/10.1345\/aph.1L426","journal-title":"Ann Pharmacother"},{"key":"3970_CR38","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1200\/JCO.2007.11.9230","volume":"26","author":"JL Glade Bender","year":"2008","unstructured":"Glade Bender JL, Adamson PC, Reid JM et al (2008) Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children\u2019s Oncology Group Study. J Clin Oncol 26:399\u2013405. https:\/\/doi.org\/10.1200\/JCO.2007.11.9230","journal-title":"J Clin Oncol"},{"key":"3970_CR39","doi-asserted-by":"publisher","unstructured":"Gorsi HS, Khanna PC, Tumblin M et al (2018) Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience. Pediatr Blood Cancer 65:e27234. https:\/\/doi.org\/10.1002\/pbc.27234","DOI":"10.1002\/pbc.27234"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-03970-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-022-03970-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-03970-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T07:31:54Z","timestamp":1650526314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-022-03970-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["3970"],"URL":"https:\/\/doi.org\/10.1007\/s11060-022-03970-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1034556\/v1","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,3]]},"assertion":[{"value":"9 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funds, grants, or other support was received. The authors have no relevant financial or non-financial interests to disclose. Dr Grill has received grant support from Hoffmann La Roche for a study with bevacizumab in pediatric high-grade gliomas.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was waived by the local Ethics Committee of Gustave Roussy (CCTIRS no 14.817) in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}